[ad_1]
The Singapore Health Sciences Authority (HSA) has approved the interim authorization of Moderna’s Covid-19 mRNA vaccine for use under the Special Pandemic Access Road (PSAR).
Last December, the Singapore Ministry of Health entered into a supply agreement with the company to secure access to the COVID-19 Moderna vaccine.
The latest development stems from the body of scientific evidence shared by Moderna, which includes data from the pivotal Phase III clinical study.
In addition to Singapore, Moderna’s vaccine has received approval from health agencies in the United States, United Kingdom, Canada, Israel, European Union, and Switzerland.
Currently, authorizations from other countries and from the World Health Organization (WHO) are under review.
Moderna CEO Stéphane Bancel said: “Today’s clearance is another important step in the global fight against Covid-19.”
“I would like to thank the Singapore Ministry of Health and the HSA for their collaboration and for the confidence they have shown in COVID-19 Vaccine Moderna with this decision.
In addition, the Swiss federal government has increased its confirmed ordering commitment for the COVID-19 Vaccine Moderna vaccine from 7.5 million to 13.5 million doses in the country.
Last August, the government announced the initial purchase of 4.5 million doses and increased to 7.5 million doses in December.
With the latest development, an additional six million doses will be delivered from June of this year, with an option to purchase doses in the first half of next year, as the company explores potential vaccine boosts to treat emerging variants.
Bancel added: “We are grateful for the confidence and support shown by the Swiss Federal Government as it strengthens its supply agreement with us.”
Last month, the Swiss Therapeutic Products Agency, Swissmedic, authorized Moderna’s Covid-19 vaccine.
[ad_2]
Source link
